Ketamine and esketamine, the S-enantiomer of the racemic mixture, have recently
generated considerable interest as potential therapeutic agents for Treatment-Resistant …

Over the last 25 years, the human endocannabinoid system (ECS) has come into the
limelight as an imperative neuro-modulatory system. It is mainly comprised of endogenous …

Background Sleep deprivation (SD) has been suggested to have a rapid antidepressant
effect. There is substantial evidence that neuroinflammation and neuroplasticity play critical …

Background Depression is a chronic psychiatric disease of multifactorial etiology, and its
pathophysiology is not fully understood. Stress and other chronic inflammatory pathologies …

The endocannabinoid (eCB) system regulates many physiological functions in the central
nervous system. Fatty acid amide hydrolase (FAAH) is an essential enzyme in the eCB …

Background Repetitive transcranial magnetic stimulation (rTMS) targeting the visual cortex
(VC) has shown antidepressant effects for major depressive disorder (MDD) in sham …

Although preliminary evidence suggests Cannabis's efficacy in symptom control for anxiety
and depression—psychiatric disorders that significantly impact mental health—much …

The endocannabinoid system is found throughout the central nervous system, and its
cannabinoids receptor 1 is critical in preventing neurotoxicity caused by N‐methyl‐D …

Major depressive disorder (MDD) stands as a significant cause of disability globally.
Cannabidiolic Acid-Methyl Ester (CBDA-ME)(EPM-301, HU-580), a derivative of …

Ketamine (KET) is recognized as rapid-acting antidepressant, but its mechanisms of action
remain elusive. Considering the role of endocannabinoids (eCB) in stress and depression …